Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (217)	6/2/2003 8:38:13 AM
From: mopgcw	Respond to of 590

From SSB: For AMGN/ABGX's ABX-EGF: As previewed, data from the interim analysis in the first 40 patients will be presented. The abstract shows data on the first 23 patients demonstrating 3 partial responders (13% response rate) and 9 stable disease (39% response rate). All 23 patients had a skin rash but it is unclear if there was a correlation between severity of skin rash and response. We expect updated interim data on 40 patients to be presented on Saturday. In the meantime, this Phase II study has completed enrollment of approximately 100 patients with results expected later this year.